Category Press Releases

Novo Nordisk’s Acquisition of Three Fill-Finish Sites from Novo Holdings A/S in Conjunction with the Catalent, Inc. Deal

Novo Nordisk has announced its agreement to acquire three fill-finish sites from Novo Holdings A/S as part of the transaction where Novo Holdings will acquire Catalent, Inc., a global contract development and manufacturing organization headquartered in Somerset, New Jersey (US).…

Read MoreNovo Nordisk’s Acquisition of Three Fill-Finish Sites from Novo Holdings A/S in Conjunction with the Catalent, Inc. Deal

FDA Fast Tracks BioNTech/DualityBio’s Cancer Drug Candidate

FDA Grants Fast Track Designation to BioNTech and DualityBio for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT325/DB-1305…

Read MoreFDA Fast Tracks BioNTech/DualityBio’s Cancer Drug Candidate

Verification of Gamma Wave Synchronization in the Human Brain via Auditory Stimulation: Academic Session at Neuroscience 2023 in the United States

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative Directors: Yoichi Ochiai and Taiichiro Murakami; referred to as “PxDT”)…

Read MoreVerification of Gamma Wave Synchronization in the Human Brain via Auditory Stimulation: Academic Session at Neuroscience 2023 in the United States

Teva Plans API Business Divestment as a Key Element of Growth-Oriented Strategy

Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…

Read MoreTeva Plans API Business Divestment as a Key Element of Growth-Oriented Strategy

Regeneron Establishes Regeneron Cell Medicines Through Acquisition of 2seventy Bio Platforms and Development Programs

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the establishment of Regeneron Cell Medicines, marking a strategic agreement with 2seventy bio, Inc. to acquire complete development and commercialization rights to its portfolio of novel immune cell therapies. This acquisition encompasses preclinical…

Read MoreRegeneron Establishes Regeneron Cell Medicines Through Acquisition of 2seventy Bio Platforms and Development Programs

FDA Approves Kite’s Manufacturing Process Change, Leading to Faster Turnaround Time for Yescarta CAR T-cell Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in…

Read MoreFDA Approves Kite’s Manufacturing Process Change, Leading to Faster Turnaround Time for Yescarta CAR T-cell Therapy

Sanofi Achieves Robust Sales and Business EPS Growth at Constant Exchange Rates, Fueled by Successful Product Launches and Progress in Immunology Pipeline

In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…

Read MoreSanofi Achieves Robust Sales and Business EPS Growth at Constant Exchange Rates, Fueled by Successful Product Launches and Progress in Immunology Pipeline